Daxor Corporation Announces Placement Of Two BVA-100 Blood Volume Analyzers

NEW YORK, NY--(Marketwired - March 13, 2015) -

Daxor Corporation, (NYSE MKT: DXR) a medical instrumentation and biotechnology company announced the placement of two instruments today.

One of the instruments was placed at the Sovereign Heart and Lung Center in Hawthorne, New Jersey. The Medical Director of the Center is John Strobeck, MD, PhD.

Dr. Strobeck has held many prestigious positions during his career. He was a member of the Board of Directors of the New Jersey Chapter of the American Heart Association, Co-Founder of the Heart Failure Society of America and previously was Chief of Cardiology at the Valley Hospital. He has spent a large part of his career working on many different research initiatives and has contributed to over 90 published works on the physiology of the heart and various causes and treatments for heart failure. As a result of having reviewed over 800 blood volume determinations on inpatients with a variety of diseases, Dr. Strobeck has extensive experience in the methods, use, and interpretation of the results.

Dr. Strobeck made the following statement regarding the placement of the BVA-100 at the Sovereign Heart and Lung Center:

“The Sovereign Heart-Lung Center is a multidisciplinary Cardiopulmonary Center specializing in the treatment of chronic forms of both cardiovascular and pulmonary disease. The Center has been noted over the years for its active heart failure program including both clinical research and advanced heart failure patient care. The addition of the Daxor BVA-100 instrument, for the purpose of accurately assessing an ill patient’s blood volume and red cell mass, will considerably improve the overall diagnostic and treatment accuracy for outpatients presenting with symptoms of fatigue, shortness of breath, and/or swelling in the lower extremities. Blood volume measurement has been shown in multiple peer-reviewed clinical studies to provide precise measurements. These measurements have been effectively applied to guide treatment and improve clinical outcomes in some of the sickest heart failure patients who have been seen in our office. I am convinced that this technique will markedly improve the chance that these ill patients will not require readmission to an acute care hospital for long periods of time.”

Dr. Joseph Feldschuh, the President and Chief Executive Officer of Daxor, said the following:

“Blood volume measurement provides the key for optimum treatment of congestive heart failure patients. Unfortunately, of such patients, 30% to 40% do not survive the first year after their initial admission to a hospital for heart failure. Very powerful drugs such as diuretics and vasodilators cause major changes in blood volume. Most patients are currently treated on the basis of physical examinations which have been shown as being an inaccurate way of assessing a patient’s blood volume status. Our goal is to make blood volume measurement a standard of care in treating such patients to avoid complications such as kidney failure caused by inappropriate use of medications.”

Daxor also signed a contract with a Hospital in Minnesota to install a BVA-100 Blood Volume Analyzer. The instrument is expected to be installed sometime within the next two months.

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with a single use diagnostic kit. The instrument is the only FDA approved semi-automated instrument to provide this test. Preliminary results can be available in 30 minutes and complete results in under an hour. To learn more about Daxor, please visit www.Daxor.com.